Expertise in
14
conditions

Zhijian J. Xiao

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020, 
Tianjin, CN 
Expertise in
14
conditions
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020, 
Tianjin, CN 

Overview

Zhijian Xiao practices practicing medicine in Tianjin, China.

Xiao is highly rated in 14 conditions, according to our data. Their clinical expertise encompasses Myelodysplastic Syndrome (MDS), Polycythemia Vera, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 292 peer reviewed articles and participating in 4 clinical trials.

Locations

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020, Tianjin, 301600, China
Other Locations
Guangdong Key Laboratory Of Environmental Pollution And Health, Guangzhou, 511443, China
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, China
No. 288, Nanjing Road, Xiaobailou, 300020, China
China
Fujian Provincial Key Laboratory Of Innovative Drug Target Research, Xiamen, 361102, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Single-group, Open-label, Multicenter, Phase I Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
A Single-group, Open-label, Multicenter, Phase I Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: June 03, 2026
Intervention Type: Drug
Study Drug: TQ05105
Study Phase: Phase 1
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
Enrollment Status: Terminated
Publish Date: April 17, 2024
Intervention Type: Drug
Study Drug: ATG-016
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

292 Total Publications

Germline DDX41 mutations and myelodysplastic neoplasms
Germline DDX41 mutations and myelodysplastic neoplasms
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 07, 2026

Frequently Asked Questions about Zhijian J. Xiao

Is Zhijian J. Xiao a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Zhijian J. Xiao is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhijian J. Xiao participate in research or clinical trials?

Yes. Zhijian J. Xiao has published 292 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Zhijian J. Xiao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xiao's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile